A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab versus Paclitaxel in Combination with Subcutaneous Trastuzumab for Stage 1 HER2-positive Breast Cancer - ATEMPT 2.0 (DF/HCC 21-159)
This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery.
The name of the study drugs involved are:
- Trastuzumab-emtansine (T-DM1, Kadcyla)
- Trastuzumab SC (Herceptin Hylecta)
- Paclitaxel
Principal Investigator(s)
Steve Lo, MD
Sponsor(s)
Dana-Farber Cancer Institute
Contact
Mary Miller, LPN at 203-358-8879 or [email protected]
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-276-2695
Stamford, CT 06902
Main: 203-276-2695